OSTX OS Therapies Inc
Pharmaceutical Preparations · NYSE · SEC CIK 1795091 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-139.4%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-513.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets296.1%
Debt / equity—
Current ratio0.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-296.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.97M | $6.07M | $7.35M | $8.80M | $3.76M | $2.50M | $1.31M | $870,469 |
| SG&A expense | $3.06M | $2.50M | $2.82M | $3.19M | $3.12M | $2.34M | $3.69M | $2.10M |
| Operating income | -$9.03M | -$8.58M | -$10.17M | -$11.99M | -$6.88M | -$4.84M | -$5.00M | -$2.97M |
| Interest expense | $621,298 | $5,581 | $75,344 | — | — | — | — | $7,556 |
| Net income | -$11.28M | -$8.63M | -$10.40M | -$13.46M | -$6.88M | -$4.54M | -$3.88M | -$2.99M |
| EBITDA | -$8.91M | -$8.45M | -$10.04M | -$11.86M | -$6.75M | -$4.73M | -$5.00M | -$2.97M |
| EPS (basic) | -0.23 | -0.20 | -0.27 | — | -0.22 | -0.19 | -0.18 | — |
| EPS (diluted) | -0.23 | -0.20 | -0.27 | — | -0.22 | -0.19 | -0.18 | — |
| Weighted avg. shares (diluted) | 48.06M | 43.90M | 38.67M | — | 31.96M | 25.11M | 21.25M | — |
| Banking | ||||||||
| Deposits | — | — | — | — | $400,000 | — | — | $150,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $431,816 | $205,035 | $917,552 | $269,830 | $1.88M | $2.80M | $2.97M | $5.53M |
| Current assets | $1.98M | $3.64M | $917,552 | $332,912 | $2.32M | $3.55M | $4.10M | $5.53M |
| PP&E, net | $405 | $1,100 | $1,795 | $2,490 | $3,185 | $3,880 | $4,575 | $5,270 |
| Intangibles | $6.13M | $6.26M | $6.38M | $6.50M | $6.86M | $6.86M | — | — |
| Total assets | $8.11M | $9.90M | $7.30M | $6.84M | $8.95M | $10.31M | $4.25M | $5.54M |
| Current liabilities | $23.91M | $20.64M | $16.95M | $11.76M | $4.15M | $3.46M | $3.54M | $4.63M |
| Total liabilities | $24.01M | $20.74M | $17.05M | $11.86M | $4.25M | $3.56M | $3.64M | $4.73M |
| Shareholders' equity | -$16.97M | -$11.91M | -$10.82M | -$6.10M | $3.64M | $4.94M | -$4.19M | -$3.27M |
| Shares outstanding | 47.07M | 45.28M | 39.28M | 37.11M | 33.27M | 29.66M | 21.35M | 20.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.65M | -$5.53M | -$4.56M | -$3.73M | -$4.71M | -$2.36M | -$3.44M | -$2.37M |
| Capital expenditure | — | — | — | $0 | $0 | $316,423 | $150,000 | — |
| Free cash flow | — | — | — | -$3.73M | -$4.71M | -$2.68M | -$3.59M | — |
| Investing cash flow | — | — | — | $0 | $0 | -$292,787 | -$173,636 | — |
| Financing cash flow | $4.88M | $4.82M | $5.21M | $2.12M | $3.78M | $2.48M | $1.05M | $6.05M |
| Depreciation & amortization | $124,938 | $124,938 | $124,938 | $124,938 | $124,938 | $112,514 | $695 | $1,390 |
| Stock-based compensation | $2.04M | $1.33M | $1.44M | $1.60M | $814,932 | $905,182 | $941,283 | $268,300 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.